Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 Mutations
Status:
Withdrawn
Trial end date:
2021-02-18
Target enrollment:
Participant gender:
Summary
This phase II trial studies the side effects and how well dabrafenib and trametinib work in
treating patients with Erdheim Chester disease that have BRAF V600 gene mutations. Dabrafenib
and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for
cell growth.